Classification of anticancer drugs -: a new system based on therapeutic targets

被引：125

作者：

Espinosa, E ^{[1
]}

Zamora, P ^{[1
]}

Feliu, J ^{[1
]}

Barón, MG ^{[1
]}

机构：

[1] Hosp La Paz, Med Oncol Serv, Madrid 28046, Spain

来源：

CANCER TREATMENT REVIEWS | 2003年 / 29卷 / 06期

关键词：

antineoplastic drugs chemotherapy; classification; monoclonal antibodies; new drugs; small molecules;

D O I：

10.1016/S0305-7372(03)00116-6

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

The arrival of a great number of new antineoplastic agents has made it necessary to reclassify all of them. Anticancer drugs may act at different levels: cancer cells, endothelium, extracellular matrix, the immune system or host cells. The tumour cell can be targeted at the DNA, RNA or protein level. Most classical chemotherapeutic agents interact with tumour DNA, whereas monoclonal antibodies and small molecules are directed against proteins. The endothelium and extracellular matrix may be affected also by specific antibodies and small molecules. (C) 2003 Elsevier Ltd. All rights reserved.

引用

收藏

页码：515 / 523

页数：9

相关论文

共 96 条

[1] Preclinical and clinical evaluation of proteasome inhibitor PS-341 for the treatment of cancer [J].

Adams, J .

CURRENT OPINION IN CHEMICAL BIOLOGY, 2002, 6 (04) :493-500

[2] Bendamustine in the treatment of chronic lymphocytic leukemia: Results and future perspectives [J].

Aivado, M ;

Schulte, K ;

Henze, L ;

Burger, J ;

Finke, J ;

Haas, R .

SEMINARS IN ONCOLOGY, 2002, 29 (04) :19-22

[3] Potential benefits of the irreversible pan-erbB inhibitor, CI-1033, in the treatment of breast cancer [J].

Allen, LF ;

Lenehan, PF ;

Eiseman, IA ;

Elliott, WL ;

Fry, DW .

SEMINARS IN ONCOLOGY, 2002, 29 (03) :11-21

[4]

*AM SOC HEM M, 2002, CLIN LYMPHOMA, V2, P209

[5]

[Anonymous], 2002, Drugs R D, V3, P28

[6] Blockade of epidermal growth factor receptor signaling on tumor cells and tumor-associated endothelial cells for therapy of human carcinomas [J].

Baker, CH ;

Kedar, D ;

McCarty, MF ;

Tsan, R ;

Weber, KL ;

Bucana, CD ;

Fidler, IJ .

AMERICAN JOURNAL OF PATHOLOGY, 2002, 161 (03) :929-938

[7]

Baselga J, 2001, EUR J CANCER, V37, pS16

[8] Neovastat (Æ-941) in refractory renal cell carcinoma patients:: report of a phase II trial with two dose levels [J].

Batist, G ;

Patenaude, F ;

Champagne, P ;

Croteau, D ;

Levinton, C ;

Hariton, C ;

Escudier, B ;

Dupont, E .

ANNALS OF ONCOLOGY, 2002, 13 (08) :1259-1263

[9] A phase I study of AMGN-0007, a recombinant osteoprotegerin construct, in patients with multiple myeloma or breast carcinoma related bone metastases [J].

Body, JJ ;

Greipp, P ;

Coleman, RE ;

Facon, T ;

Geurs, F ;

Fermand, JP ;

Harousseau, JL ;

Lipton, A ;

Mariette, X ;

Williams, CD ;

Nakanishi, A ;

Holloway, D ;

Martin, SW ;

Dunstan, CR ;

Bekker, PJ .

CANCER, 2003, 97 (03) :887-892

[10] Bisphosphonates for cancer patients: why, how, and when? [J].

Body, JJ ;

Mancini, I .

SUPPORTIVE CARE IN CANCER, 2002, 10 (05) :399-407

← 1 2 3 4 5 6 7 8 9 10 →